Contact this trialFirst, we need to learn more about you.
Durvalumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial will test whether it is safe to give patients durvalumab and tremelimumab, immunotherapies that activate the body's own immune system to fight cancer, after they have completed standard treatment for NSCLC and when they have detectable ctDNA in their blood.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.